Society for Translational Medicine Consensus on Postoperative Management of EGFR-Mutant Lung Cancer (2019 Edition)

Wenhua Liang; Kaican Cai; Chun Chen; Haiquan Chen; Wentao Fang; Junke Fu; Xiangning Fu; Shugeng Gao; Jian Hu; Yunchao Huang; Ganning Jiang; Wenjie Jiao; Shanqing Li; Gaofeng Li; Hecheng Li; Hui Li; Xiaofei Li; Naixin Liang; Deruo Liu; Hongxu Liu; Jun Liu; Lunxu Liu; Yang Liu; Qingquan Luo; Haitao Ma; Weimin Mao; Zhongmin Peng; Guibin Qiao; Guoguang Shao; Lijie Tan; Qunyou Tan; Qun Wang; Changli Wang; Qingchen Wu; Shidong Xu; Songtao Xu; Lin Xu; Yue Yang; Fenglei Yu; Baijiang Zhang; Lanjun Zhang; Bo Zhao; Xiuyi Zhi; Alessandro Brunelli; René Horsleben Petersen; Chia-Chuan Liu; Biagio Ricciuti; Giulio Metro; Alessandro Tuzi; Matteo B. Suter; Matthew Evison; Nobuhiko Seki; Shinji Sasada; Takhiro Izumo; William Chi-Shing Cho; Jianxing He

Disclosures

Transl Lung Cancer Res. 2019;8(6):1163-1173. 

In This Article

Abstract and Introduction

Introduction

Non-small cell lung cancer (NSCLC) is the most common and fatal tumor worldwide, with 2.1 million new cases and 1.77 million deaths per year.[1] With the wider application of examination approaches and the improvement of health awareness, higher proportions of surgically resectable early and mid-stage lung cancers have been detected. In overall, only 50% of patients have been cured after radical resection. In other cases, however, NSCLC is highly active and recurrence and/or metastasis can easily occur after surgery. In these patients, systemic therapy as a postoperative adjuvant therapy is required to eliminate or reduce residual micro-lesions to lower the risk of recurrence; meanwhile, the patients should be closely monitored to detect early recurrence. EGFR mutation is a major mutation type in lung cancer, and is seen in about 40% of lung cancer cases in Asia.[2] Compared with wild types and other mutation types, EGFR-mutant NSCLC has its unique biological properties and drug susceptibilities, and thus requires specific diagnosis and treatment strategies. This expert consensus aims to review the current evidence and provide recommendations on key issues.

A consensus and guideline development panel, with its members including top thoracic surgeons and oncologists all around the world, was established to decide the methodologies, processes, levels of evidence, and related recommendations. The panel members proposed the core clinical issues in the consensus document and wrote and submitted the outlines to the panel for approval. The panel carried out a problem-oriented literature search for articles published since 1997 in Chinese and foreign databases. The level of evidence was defined using the following criteria: Categories of Evidence and Consensus, Category 1: based upon high-level evidence, there is uniform consensus that the intervention is appropriate; Category 2A: based upon lower-level evidence, there is uniform consensus that the intervention is appropriate; Category 2B: based upon lower-level evidence, there is consensus that the intervention is appropriate; Category 3: based upon any level of evidence, there is major disagreement that the intervention is appropriate. The strength of recommendations was classified as strong or weak according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system,[3] and the recommendation statement was composed based on the real-world evidence. A "strong" recommendation generally refers to recommendations based on high-level evidence with consistency between clinical behavior and outcome expectancy; in contrast, a "weak" recommendation is typically based on low-level evidence with uncertainty between clinical behavior and outcome expectancy. After the first draft had been completed, all the panel members were involved in revising and finalizing this document.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....